Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608710 · ClinicalTrials.gov registry record · Phase 1
RDEA3170 PK/PD Study
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02608710 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 40 participants.
The verdict
NCT02608710, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses
Interventions
- DRUG RDEA3170 4.5 mg
- DRUG RDEA3170 6 mg
- DRUG RDEA3170 12 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608710
The ClinicalTrials.gov registry entry for NCT02608710 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which RDEA3170 4.5 mg is the first listed.
NCT02608710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02608710 about?
NCT02608710 is a clinical study titled "RDEA3170 PK/PD Study". The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses
What is the current status of trial NCT02608710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-11. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02608710?
The interventions under investigation include: RDEA3170 4.5 mg (DRUG), RDEA3170 6 mg (DRUG), RDEA3170 12 mg (DRUG).
Who is sponsoring clinical trial NCT02608710?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.